Smith & Nephew PLC(SNNUF)- OTCPK - Current
  • Oct. 13, 2014, 7:14 AM
    • Smith & Nephew's (NYSE:SNN) (OTCQB:SNNUF) living cell therapy product candidate, HP802-247, failed to achieve its primary endpoint in a U.S. Phase 3 clinical trial to assess its safety and efficacy as a treatment for patients with venous leg ulcers. The primary endpoint was a statistically significant improvement in healing compared to placebo.
    • The reported results are top-line data. A full analysis will be completed in the next few months to determine what went wrong considering the strongly positive Phase 2a/2b results. A second Phase 3 being conducted in Europe will continue.
    • Hp802-247 is an allogenic living cell bio-formulation of irradiated keratinocytes and fibroblasts in a human fibrin suspension. It is designed to work with the body's own cells to stimulate healing.
    | Oct. 13, 2014, 7:14 AM
  • Jul. 21, 2014, 7:15 AM
    • Bloomberg reports that, according to analysts, there are three ex-U.S. medical firms that should be high on the target acquisition list for tax inversion deals. Ireland-based Perrigo (NYSE:PRGO), Switzerland-based Actelion and U.K.-based Smith & Nephew Plc (NYSE:SNN) (OTCQB:SNNUF) are all attractive targets. Observers believe there will be more acquisitions consummated before Congress puts limits on the maneuvers.
    • Stryker (NYSE:SYK) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE:PFE) may make another run at AstraZeneca (NYSE:AZN) after the end of the cool-off period.
    | Jul. 21, 2014, 7:15 AM | 1 Comment
Company Description
Smith & Nephew is a medical devices company engaged in the manufacture and sale of products in the orthopaedics, endoscopy, and wound management business sectors. Products include orthopaedic knee and hip implants, as well as trauma products, arthroscopy and advanced wound care products. These... More
Sector: Healthcare
Industry: Health Care Plans
Country: United Kingdom